UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer

British journal of cancer, 2012-03, Vol.106 (7), p.1249-1258

2012

Volltextzugriff (PDF)

Thrombopoietin receptor is required for the oncogenic function of CALR mutants

Leukemia, 2016-08, Vol.30 (8), p.1759-1763

2016

Volltextzugriff (PDF)

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin

Leukemia, 2016-08, Vol.30 (8), p.1775-1778

2016

Volltextzugriff (PDF)

JAK/STAT signaling in hematological malignancies

Oncogene, 2013-05, Vol.32 (21), p.2601-2613

2013

Volltextzugriff (PDF)

Aberrant signal transduction pathways in myeloproliferative neoplasms

Leukemia, 2008-10, Vol.22 (10), p.1828-1840

2008

Volltextzugriff (PDF)

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

Leukemia, 2017-05, Vol.31 (5), p.1023-1038

2017

Volltextzugriff (PDF)

Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation

Oncogene, 2015-03, Vol.34 (10), p.1323-1332

2015

Volltextzugriff (PDF)

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

Leukemia, 2017-12, Vol.31 (12), p.2853-2853

2017

Volltextzugriff (PDF)

JAK kinases overexpression promotes in vitro cell transformation

Oncogene, 2008-03, Vol.27 (11), p.1511-1519

2008

Volltextzugriff (PDF)

Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms

Leukemia, 2016-05, Vol.30 (5), p.1214-1216

2016

Volltextzugriff (PDF)

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution

Leukemia, 2015-01, Vol.29 (1), p.249-252

2015

Volltextzugriff (PDF)

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

Haematologica (Roma), 2011-06, Vol.96 (6), p.845-853

2011

Volltextzugriff (PDF)

An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis

Leukemia, 2017-08, Vol.31 (8), p.1838-1839

2017

Volltextzugriff (PDF)

Inhibitors of Amyloid Toxicity Based on beta -sheet Packing of A beta 40 and A beta 42

Biochemistry (Easton), 2006-05, Vol.45 (17), p.5503-5516

2006

Volltextzugriff (PDF)

Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain

The EMBO journal, 1999-06, Vol.18 (12), p.3334-3347

1999

Volltextzugriff (PDF)

CLINICAL IMPLICATIONS OF JAK2 MUTATIONS IN MYELOPROLIFERATIVE DISORDERS

Acta clinica belgica (English ed. Online), 2008-03, Vol.63 (2), p.93-98

2008

Volltextzugriff (PDF)

The N-Terminal Domain of Janus Kinase 2 Is Required for Golgi Processing and Cell Surface Expression of Erythropoietin Receptor

Molecular cell, 2001-12, Vol.8 (6), p.1327-1338

2001

Volltextzugriff (PDF)

Ligand-Independent Oligomerization of Cell-Surface Erythropoietin Receptor is Mediated by the Transmembrane Domain

Proceedings of the National Academy of Sciences - PNAS, 2001-04, Vol.98 (8), p.4379-4384

2001

Volltextzugriff (PDF)

Stem cell generation and choice of fate: role of cytokines and cellular microenvironment

Journal of cellular and molecular medicine, 2000-10, Vol.4 (4), p.233-248

Constantinescu, S.N.

2000

Volltextzugriff (PDF)

Introduction to 'A special spotlight review series on BCR-ABL-negative myeloproliferative neoplasms'

Leukemia, 2008-01, Vol.22 (1), p.1-1

2008

Volltextzugriff (PDF)

JAK2, the JAK2 V617F mutant and cytokine receptors

Pathologie biologie (Paris), 2007-03, Vol.55 (2), p.88-91

2007

Volltextzugriff (PDF)

Transforming Growth Factor β -Induced Phosphorylation of Smad3 is Required for Growth Inhibition and Transcriptional Induction in Epithelial Cells

Proceedings of the National Academy of Sciences - PNAS, 1997-09, Vol.94 (20), p.10669-10674

1997

Volltextzugriff (PDF)

Role of Interferon α/β Receptor Chain 1 in the Structure and Transmembrane Signaling of the Interferon α/β Receptor Complex

Proceedings of the National Academy of Sciences - PNAS, 1994-09, Vol.91 (20), p.9602-9606

1994

Volltextzugriff (PDF)

The Erythropoietin Receptor Cytosolic Juxtamembrane Domain Contains an Essential, Precisely Oriented, Hydrophobic Motif

Molecular cell, 2001-02, Vol.7 (2), p.377-385

2001

Volltextzugriff (PDF)

Erratum: Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

Leukemia, 2017-12, Vol.31 (12), p.2853-2853

2017

Volltextzugriff (PDF)

1 – 25 von 1.017

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(714)
Mit Volltextzugriff
(729)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer

Thrombopoietin receptor is required for the oncogenic function of CALR mutants

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin

JAK/STAT signaling in hematological malignancies

Aberrant signal transduction pathways in myeloproliferative neoplasms

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

JAK kinases overexpression promotes in vitro cell transformation

Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis

Inhibitors of Amyloid Toxicity Based on beta -sheet Packing of A beta 40 and A beta 42

Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain

CLINICAL IMPLICATIONS OF JAK2 MUTATIONS IN MYELOPROLIFERATIVE DISORDERS

The N-Terminal Domain of Janus Kinase 2 Is Required for Golgi Processing and Cell Surface Expression of Erythropoietin Receptor

Ligand-Independent Oligomerization of Cell-Surface Erythropoietin Receptor is Mediated by the Transmembrane Domain

Stem cell generation and choice of fate: role of cytokines and cellular microenvironment

Introduction to 'A special spotlight review series on BCR-ABL-negative myeloproliferative neoplasms'

JAK2, the JAK2 V617F mutant and cytokine receptors

Transforming Growth Factor β -Induced Phosphorylation of Smad3 is Required for Growth Inhibition and Transcriptional Induction in Epithelial Cells

Role of Interferon α/β Receptor Chain 1 in the Structure and Transmembrane Signaling of the Interferon α/β Receptor Complex

The Erythropoietin Receptor Cytosolic Juxtamembrane Domain Contains an Essential, Precisely Oriented, Hydrophobic Motif

Erratum: Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

Suchergebnisse filtern